Winston Pharmaceuticals, Inc.
WPHM · OTC
12/31/2009 | 12/31/2008 | 9/30/2007 | 9/30/2006 | |
|---|---|---|---|---|
| Revenue | $1,395 | $453 | $0 | $0 |
| % Growth | 208.2% | – | – | – |
| Cost of Goods Sold | $9 | $9 | $0 | $209 |
| Gross Profit | $1,386 | $444 | $0 | -$209 |
| % Margin | 99.4% | 98.1% | – | – |
| R&D Expenses | $2,063 | $3,496 | $0 | $0 |
| G&A Expenses | $2,064 | $0 | $0 | $0 |
| SG&A Expenses | $2,064 | $2,182 | $215 | $210 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $9 | $9 | $0 | $7 |
| Operating Expenses | $4,127 | $5,678 | $215 | $217 |
| Operating Income | -$2,741 | -$5,234 | -$215 | -$426 |
| % Margin | -196.6% | -1,156.6% | – | – |
| Other Income/Exp. Net | $86 | $93 | $35 | -$39 |
| Pre-Tax Income | -$2,655 | -$5,142 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,655 | -$5,142 | -$180 | -$465 |
| % Margin | -190.4% | -1,136.2% | – | – |
| EPS | -0.04 | -0.1 | -0.08 | -0.8 |
| % Growth | 60% | -25% | 90% | – |
| EPS Diluted | -0.04 | -0.1 | -0.08 | -0.8 |
| Weighted Avg Shares Out | 61,258 | 53,422 | 1,649 | 607 |
| Weighted Avg Shares Out Dil | 61,258 | 53,422 | 1,649 | 607 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10 | $91 | $35 | $0 |
| Interest Expense | $0 | $0 | $0 | $39 |
| Depreciation & Amortization | $9 | $9 | $15 | $7 |
| EBITDA | -$2,732 | -$5,226 | -$200 | -$418 |
| % Margin | -195.9% | -1,154.7% | – | – |